Figma Shares Indicated To Open $95/$100
Khalifa Sammy, the Chief Technology Officer of Vicarious Surgical Inc. (NYSE:RBOT), a company currently valued at $82.72 million and showing strong momentum with a 110% gain over the past six months, recently sold a portion of the company’s Class A common stock. According to a Form 4 filing with the Securities and Exchange Commission, Sammy sold 754 shares on February 20, 2025, generating a total of $10,955. The shares were sold at a weighted average price of $14.5305 per share, with individual transaction prices ranging from $14.085 to $15.50. InvestingPro analysis indicates the company maintains a healthy liquidity position with a current ratio of 7.44, suggesting strong ability to meet short-term obligations.
The sale was executed to cover tax withholding obligations related to the vesting of restricted stock units granted on May 19, 2022. Following this transaction, Sammy retains ownership of 36,927 shares directly.
These transactions are part of the routine financial activities of company executives, providing insight into their personal financial management and relationship with the company. Investors often monitor such filings to gauge executive confidence in the company’s future performance.
In other recent news, Vicarious Surgical Inc. announced that its Chief Operating Officer, John Mazzola, will retire on April 1, 2025. Mazzola’s role will be taken over by Randy Clark, the current President of the company. In addition, Vicarious Surgical has entered into a consulting agreement with its former Chief Financial Officer, William Kelly. This agreement, effective from January 17, 2025, will see Kelly providing advisory services until December 31, 2028, with compensation details outlined for different phases of the contract. Kelly will retain vesting rights to his stock options and restricted stock units until June 30, 2025. These changes are part of Vicarious Surgical’s ongoing strategic developments. The company continues to focus on its innovative surgical technology and is preparing for its first clinical use cases and a pivotal trial.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.